Vimarsana
Biggest News Aggregation in the World

Page 3 - Seqirus Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Seqirus Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Seqirus Inc Today - Breaking & Trending Today

Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response - Vimarsana News

Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response

/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement...

Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response - Vimarsana News

Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response

/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement...

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine - Vimarsana News

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

/PRNewswire/ -- The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against...

Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months - Vimarsana News

Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months

/PRNewswire/ -- Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug...

The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents &#x2265;2 to <18 Years of Age - Vimarsana News

The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents &#x2265;2 to <18 Years of Age

/PRNewswire/ -- Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of...